Treatment Strategies: Managing the Disease

Treating non-transplant bronchiolitis obliterans is different from treating common lung conditions like asthma or COPD. Because the disease involves physical scarring (fibrosis) of the tiny airways, the goal of treatment is usually to stabilize your lung function and prevent further damage rather than “curing” the existing scars ^[1][2].

The most effective treatment strategy depends almost entirely on the “bucket” or cause of your condition.

The First Step: Stop the Trigger

For many people, the most powerful “medicine” is simply removing the cause of the injury.

• Inhalational/Occupational: If your condition was caused by breathing in toxic fumes, dusts, or flavoring chemicals like diacetyl, the absolute priority is complete removal from that environment ^[3][4]. Continuing even low-level exposure can lead to further scarring and decline ^[5]. You should ask for a referral to an occupational or environmental medicine specialist to help document your exposure, navigate workplace safety, and discuss necessary accommodations.
• Drug-Induced: If a medication like an immune-checkpoint inhibitor is suspected, you must never stop the prescribed drug on your own. Abruptly stopping therapies for cancer or severe autoimmune disease carries severe, life-threatening risks. You must contact your prescribing specialist immediately so they can coordinate with a pulmonologist to make a careful risk-benefit decision and create an alternative treatment plan. While this may not reverse existing damage, it is essential to prevent the “insult” to your lungs from continuing ^[6].

Managing Autoimmune-Related Cases

When bronchiolitis obliterans is caused by an underlying condition like rheumatoid arthritis or Sjögren’s syndrome, the focus shifts to calming the immune system ^[7]. This should be coordinated with a rheumatologist.

• Immunosuppression: Doctors may use medications like corticosteroids (prednisone), cyclophosphamide, or rituximab to reduce inflammation ^[1][7]. These are specialist-directed, often investigational options, as evidence for their use in non-transplant cases is limited and heterogeneous.
• Mixed Results: It is important to have realistic expectations. While these drugs can sometimes slow or stop the progression of the disease, many patients do not see a major improvement in their breathing because the existing scar tissue remains ^[1]. Furthermore, these drugs carry substantial risks for infection and organ toxicity.

Treatments for Post-Infectious (PIBO)

In cases that follow a severe childhood infection, treatment is often focused on supporting the lungs while the child grows.

• Steroid Pulses and IVIG: Some pediatric specialists use high-dose “pulses” of IV steroids or Intravenous Immunoglobulin (IVIG)—a product made from blood antibodies—to help regulate the immune response ^[8][9]. Results are mixed, but some children show significant clinical improvement and a reduced need for extra oxygen ^[8][9]. Note that this evidence applies primarily to pediatric PIBO and should not be assumed as standard for adult occupational disease.
• Supportive Care: This includes physical rehabilitation, ensuring proper nutrition, and staying up-to-date on all vaccinations to prevent new lung infections that could cause more damage ^[10][11].

Common Medications and Their Evidence

You may be prescribed medications that are common in other lung diseases, but their role here is more limited.

• Bronchodilators (Inhalers): These “rescue” or “maintenance” inhalers help relax the muscles around the airways. While they often don’t fix the “fixed” obstruction of bronchiolitis obliterans, they may provide some symptom relief if you have a “reversible” component to your breathing issues or coexisting asthma ^[12][11].
• Macrolides (Azithromycin): This antibiotic is sometimes used for its anti-inflammatory properties. While it is a standard treatment for transplant-related lung disease, the evidence for it in non-transplant cases is still emerging, mostly comes from small, individual case studies, and is not a proven routine treatment ^[13][12].
• Corticosteroid Inhalers: These may be used to reduce surface-level inflammation in the airways, especially in children with post-infectious disease, though they are not recommended as a “stand-alone” maintenance therapy for fixed scarring ^[14][11].

When to Consider a Lung Transplant

For some patients, the disease may continue to progress despite all treatments, leading to end-stage lung failure.

• Evaluation: Referral is highly individualized and depends on your trajectory, gas exchange, exercise capacity, and comorbidities, rather than a single FEV1 cutoff. A stable patient is not automatically headed toward transplant ^[15].
• Timing: Referral is often done early so the transplant team can get to know you and monitor your progress. A transplant is considered an option when other treatments have failed, disease is consistently progressive, and quality of life is significantly impacted ^[15][16].

Treatment Strategy by Cause